Sharemaestro company-news research for BeiGene, Ltd. (ONC), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Provisional evidence
Company news sentiment
Latest ONC news and sentiment
BeiGene, Ltd.
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
Early balanced news score
6 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone66/100
→
Published 30-day score51/100
Latest source headline
Truist Financial Maintains BeiGene(ONC.US) With Buy Rating, Announces Target Price $420
Moomoo · 09 Oct 2026 05:42
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
6 current stories are mapped specifically to ONC.
The score uses 3 publishers rather than depending on one outlet.
What limits the score
The stories agree, but freshness-weighted evidence is only 0.094.
Confidence is 19/100, below the threshold for a firm score.
51/100
News scoreEarly balanced news score
19/100
Confidencethin evidence
95%/100
Company news6 company stories
88/100
Story agreement12/100 difference
News history
Daily score and story count over 30 days
16 Sep01 Oct15 Oct
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence2
0.094 after freshness weightingSource breadth60
3 independent publishersCompany relevance95
share tied directly to this companyFreshness23
recency-weighted evidenceAgreement88
how closely stories agreePublisher mix45
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks16 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
17 Apr14 Jul09 Oct
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
09 Oct 202653USD 354.47-1.0%
02 Oct 202652USD 358.07-0.8%
25 Sep 202651USD 360.85+2.9%
18 Sep 202654USD 350.84+1.2%
11 Sep 202659USD 346.51-3.3%
04 Sep 202662USD 358.26-2.3%
28 Aug 202662USD 366.73-2.1%
21 Aug 202655USD 374.47+7.8%
Provisional evidence
News subjects
What is shaping the score
Analyst action732 stories · 33%
Market update412 stories · 33%
Earnings601 stories · 17%
Balance sheet411 stories · 17%
Source mix
Where the evidence comes from
Moomoo723 stories · 50%
AD HOC NEWS412 stories · 33%
Simply Wall Street601 stories · 17%
Recurring subjects
Subjects appearing most often
Life Sciences6Financial Markets5Earnings3Finance1
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
20 Jun50 neutral11 Oct 18:12
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 11 Oct 18:12 | 52 | -1 | 23/100 (-4) | 6 (-2) | Provisional |
| 09 Oct 23:59 | 53 | +0 | 27/100 (-2) | 8 (-3) | Provisional |
| 01 Oct 23:59 | 53 | +1 | 29/100 (+2) | 11 (-2) | Provisional |
| 26 Sep 23:59 | 52 | +0 | 27/100 (+1) | 13 (-5) | Provisional |
| 23 Sep 23:59 | 52 | +0 | 26/100 (-1) | 18 (+1) | Provisional |
| 20 Sep 23:59 | 52 | -7 | 27/100 (-5) | 17 (-5) | Provisional |
| 11 Sep 23:59 | 59 | +3 | 32/100 (+4) | 22 (-2) | Provisional |
| 10 Sep 23:59 | 56 | -5 | 28/100 (-4) | 24 (-5) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 6 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
Which subjects lean each way
A subject can carry both supportive and cautious news.
SubjectCautious ← 0 → Constructive
Analyst action2 stories
0.0%70.4%
Balance sheet1 story
15.0%0.0%
Earnings1 story
0.0%13.5%
Market update2 stories
1.1%0.0%
Each side uses the same scale: 0–70.4% of the retained directional evidence.
Where the influence comes from
71.4%largest publisher shareA concentrated reading can depend heavily on one publisher.
Publisher groups follow the scoring rules. Company disclosures share one group; syndicated stories are consolidated before weighting.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
72/100 tone
Truist Financial has reiterated its Buy rating on BeiGene (ONC.US) and set a price target of $420. This indicates the firm's continued confidence in the pharmaceutical company's stock performance.
61.1% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
Truist Financial has reiterated its Buy rating on BeiGene (ONC.US) and set a price target of $420. This indicates the firm's continued confidence in the pharmaceutical company's stock performance.
- Published
- 09 Oct 2026 05:42
- News subject
- Analyst action
- Why this score
- Buy Rating
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 54/100
- 30-day weight
- 61.1% of directional evidence · 6.1d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinanceLife Sciences
77/100 tone
J.P. Morgan has reiterated its Buy rating for BeiGene (ONC.US) and increased its target price to $445. This positive adjustment by the investment bank reflects continued confidence in the biopharmaceutical company's financial outlook and growth prospects.
9.2% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
J.P. Morgan has reiterated its Buy rating for BeiGene (ONC.US) and increased its target price to $445. This positive adjustment by the investment bank reflects continued confidence in the biopharmaceutical company's financial outlook and growth prospects.
- Published
- 01 Oct 2026 16:27
- News subject
- Analyst action
- Why this score
- Buy Rating
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 50/100
- 30-day weight
- 9.2% of directional evidence · 13.6d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
40/100 tone
A director at BeiGene (ONC.US) has sold 68,000 shares of common stock for a total of US$11.32 million. This transaction occurred at an average price of US$166.45 per share.
1.1% of directional evidence
Low story strength
Scoring detailsDirect company coverage
A director at BeiGene (ONC.US) has sold 68,000 shares of common stock for a total of US$11.32 million. This transaction occurred at an average price of US$166.45 per share.
- Published
- 01 Oct 2026 00:02
- News subject
- Market update
- Why this score
- Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 34/100
- 30-day weight
- 1.1% of directional evidence · 14.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
60/100 tone
BeOne Medicines (ONC) has garnered attention following its rebrand from BeiGene, Ltd. in May 2025, maintaining a strong oncology focus. While the company's strong revenue growth and a fair value of $433.02 suggest it is undervalued by 17%, its high P/E ratio of 62.6x, compared to an indus…
13.5% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
BeOne Medicines (ONC) has garnered attention following its rebrand from BeiGene, Ltd. in May 2025, maintaining a strong oncology focus. While the company's strong revenue growth and a fair value of $433.02 suggest it is undervalued by 17%, its high P/E ratio of 62.6x, compared to an industry average of 17.3x, indicates potential valuation risk. The article highlights both the optimistic growth narrative driven by its best-in-class oncology therapies and the risks associated with competition and drug pricing pressures.
- Published
- 26 Sep 2026 15:50
- News subject
- Earnings
- Why this score
- Operating growth, Positive valuation view
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 36/100
- 30-day weight
- 13.5% of directional evidence · 18.6d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
59/100 tone
Market update
BeiGene stock gains 2.16 percent as biotech shares rise
BeiGene stock increased by 2.16 percent in Hong Kong trading on September 22, 2026, as the broader biotechnology sector also saw gains. While this reflects a positive market signal, the article emphasizes that the company's financial performance and operating figures remain the critical m…
<0.1% of directional evidence
Low story strength
Scoring detailsDirect company coverage
BeiGene stock increased by 2.16 percent in Hong Kong trading on September 22, 2026, as the broader biotechnology sector also saw gains. While this reflects a positive market signal, the article emphasizes that the company's financial performance and operating figures remain the critical metrics for investors to assess its valuation, rather than relying solely on sector-driven movements. The gain was noted to be smaller than some other biotech advances on the same day, suggesting a sector-wide uplift rather than a company-specific event.
- Published
- 23 Sep 2026 00:19
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 31/100
- 30-day weight
- <0.1% of directional evidence · 22.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
41/100 tone
BeiGene Ltd. (BGNE) stock is holding steady despite recent quarterly losses, as investors weigh the company's expanding oncology pipeline against its ongoing cash burn. While revenue continues to grow, operating expenses keep the company in the red, underscoring the long path to profitabi…
15% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
BeiGene Ltd. (BGNE) stock is holding steady despite recent quarterly losses, as investors weigh the company's expanding oncology pipeline against its ongoing cash burn. While revenue continues to grow, operating expenses keep the company in the red, underscoring the long path to profitability. Analysts focus on pipeline strength and global partnerships, but also highlight the need for continued funding and the risks associated with clinical development and commercialization.
- Published
- 20 Sep 2026 13:03
- News subject
- Balance sheet
- Why this score
- Negative financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 38/100
- 30-day weight
- 15% of directional evidence · 24.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
Earlier company news
ONC news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 64 older ONC headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to ONC, but the headline and available text are not mainly about BeiGene, Ltd.. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of ONC sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.